International Society

ISCITIANTED

Cell & Gene Therapy®

ESTABLISHED 1992

2021 INDUSTRY MEMBERSHIP OVERVIEW

INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY OVERVIEW

Established in 1992, ISCT is the global steward fostering cell and gene therapy translation to the clinic. Comprised of over 2400 cell therapy experts across five geographic regions and representation from over 60 countries, ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation.

ISCT leads the field in the translational aspects of developing cell-based therapeutics, advancing scientific research into innovative treatments for patients. Through long-term strategic relationships with global regulatory agencies, academic institutions, and industry partners, ISCT has built a unique collaborative environment that advances three key areas of clinical translation: Academia, Regulatory and Commercialization.

Our Three Pillars ACADEMIA REGULATORY & COMMERCIALIZATION Scientific Committees: **QUALITY OPERATIONS** Commercialization MESENCHYMAL STROMAL CELL Global Regulatory Task Force: Committee: LRA NORTH AMERICA BUSINESS MODELS AND GASTROINTESTINAL LRA AUSTRALIA & NEW ZEALAND MARKET ACCESS AND HEMATOPOIETIC STEM CELL PATIENT ADVOCACY TARGETED ORGAN Lab Practices PROCESS AND PRODUCT Committee (LPC) DEVELOPMENT MUSCULOSKELETAL THERAPIES

MISSION:

To improve lives through safe and effective cell and gene therapies.

VISION:

To drive clinical translation of cell and gene therapies worldwide.

VALUES:

- Promote innovation in translational research
- •Strive for excellence in everything we do
- Respect and support diversity and inclusivity
- Uphold the highest ethical standards
- Serve our members and advocate for our society



ISCT Membership is comprised of **2400+** professionals from around the globe.

Cytotherapy, the official journal of ISCT, is a leading publication in the Cell and Gene Therapy sector, with a growing impact factor at 4.218



THE SOCIETY HAS BEEN ADVANCING CELL THERAPY SINCE 1992

ISCT TRANSLATIONAL FOCUS



Translational Research

Preclinical Development

Clinical (Ph I, II, III)

Commercialization and Patient Access



GLOBAL

REGULATORY

TASK FORCE

BOARD OF DIRECTORS

Strategic Advisory Council Executive Management Committee

Nominations Committee

Finance and Audit Committee

Global Government and Public Relations Committee

PRESIDENTIAL TASK FORCE
ON THE USE OF UNPROVEN
AND/OR UNETHICAL CELL AND
GENE THERAPY

LAB PRACTICES COMMITTEE

ADVANCED PRACTICE PROFESSIONALS COMMITTEE

EARLY STAGE PROFESSIONALS COMMITTEE

REGIONS

- Asia
- Australia/NZ
- Europe
- North America
- South & Central America

REGIONAL LRA* COMMITTEES

- Australia/NZ
- Europe
- North America

SCIENTIFIC COMMITTEES

- Exosomes
- 4 Gastrointestinal
- Hematopoietic Stem Cell
- Immuno & Gene Therapy
- Mesenchymal Stem Cell
- Orthopedic &
 Musculoskeletal Therapies
- Targeted Organ

COMMERCIALIZATION COMMITTEE

- Business Models
 and Investments
- Market Access and Patient Advocacy
- Process and Product
 Development

THE REACH OF ISCT IS FAR AND WIDE

Connecting Global Networks of Cell Therapy Experts

With members in over 60 countries, ISCT actively collaborates with organizations worldwide to deliver programs and service that facilitate education and networking for our members, and for the cell and gene therapy field at large.

ISCT Co-Founded Organizations:





Partner Organizations:



ahcta

ahcta alliance for harmonisation of cellular therapy accreditation





Convention







European infrastructure for translational medicine













WHY JOIN THE ISCT INDUSTRY MEMBERSHIP PROGRAM?

Access a global network of cell therapy Key Opinion Leaders

- Attend exclusive networking events with thought leaders from industry, academia, clinical and regulatory settings
- Find your next partnership with a company or academic center through the diverse ISCT network

Increase visibility for your company amongst leading organizations

- Industry community members include leading therapeutic developers, CDMOs, tools, service, and product providers.
- Expert Commercialization and Subcommittee members include C-level and senior executives, investors, esteemed academic and subject matter experts.

Contribute to consensus-building educational resources

- ISCT publications, webinars, and reports set industry standards on critical topics including raw materials, COGs, investor perceptions, potency, and more.
- Lead a project with fellow members and educate the industry on your most pressing challenges

Reach translational experts across the ISCT membership

- Recruit top talent through the ISCT Career Center
- Members only networking database to connect with global cell therapy leaders and members
- Distribute marketing materials to 2400+ ISCT members





MEMBERSHIP HAS ITS BENEFITS

Collaborate with global organizations to tackle prominent cell therapy industry issues

Commercialization Committee

ISCT Committee comprised of industry members and invited academic experts that drives the Society's industry impact and provides networking opportunities for members including access to guest speakers, discussion of current industry events, and acts as forum for tackling key barriers in the path to commercialization.

Commercialization Subcommittees:

- Business Models and Investment
- Process and Product Development
- Market Access and Patient Advocacy

Unparalleled networking events

Commercialization Signature Series

Annual event for 40-50 individuals, by invitation only, consisting of ISCT Industry Patrons and Partners, invited academia, and other key opinion leaders with an objective to tackle and discuss high profile issue in the field.

Industry Networking Event

An exclusive networking event that takes place during an evening reception at the ISCT Annual Meeting each year. Past events have been hosted at the House of Commons (UK), Ambassador's residences, etc.



INDUSTRY MEMBERSHIP LEVELS & BENEFITS

	Industry Networking Event	Commercialization Signature Series	Commercialization Committee	Commercia Sub-Comm		Additional Marketing Features	
Patron \$10,500 5 Individual Membership (incl voting rights)	2 Invitations	2 Invitations	1 Seat	3 Seats	• 1 Co • 1 Jo	urvey Eblast to ISCT membership (\$3,500 value) orporate E-blast to ISCT membership (\$2,500 value) ob Posting on ISCT Career Center (\$500 value) d in Telegraft, ISCT's member e-newsletter (\$1,000 value)	
Partner \$8,000	1 Invitation	1 Invitation	1 Seat	2 Seats	• 1 Jo	orporate E-blast to ISCT membership (\$2,500 value) bb Posting on ISCT Career Center (\$500 value)	
3 Individual Membership (incl voting rights)		All indivi	dual members rece	eive:	 1 Ad in Telegraft, ISCT's member e-newsletter (\$1,000 val 		

- Access to all ISCT member web resources
- Member discounted rates to all ISCT meetings and events
- Access to ISCT Member Networking Database

- Subscription to Telegraft members only newsletter
- Annual Subscription to *Cytotherapy*, ISCT official scientific journal



INDUSTRY MEMBERSHIP LEVELS & BENEFITS

(incl voting rights)

	Industry Networking Event	Commercialization Signature Series	Commercialization Committee	Commercialization Sub-Committees	Additional Marketing Features
Supporter \$5,400	1 Invitation	Access not included at this level	Access not included at this level	1 Seat	 1 Job Posting on ISCT Career Center (\$500 value) 1 Ad in Telegraft, ISCT's member e-newsletter (\$1,000 value)
2 Individual Memberships (incl voting rig					
Contributo		Access not included	Access not included	Access not included	 1 Job Posting on ISCT Career Center (\$500 value) 1 Ad in Telegraft, ISCT's member e-newsletter
2 Individual Memberships		at this level	at this level	at this level	(\$1,000 value)

COMMITTTEES DRIVING THE ISCT INDUSTRY COMMUNITY

Commercialization Committee

- Drives the strategy of ISCT Industry Community and curates programming focused on building consensus on barriers to cell and gene therapy commercialization.
- Comprised of senior executives and invited academic experts <u>View current roster</u>
- Monthly meetings feature guest speakers, discussion on current events, and initiative planning.

Process and Product Development (PPD) Subcommittee

- Addresses best practices for therapeutic cell-based products, assesses emerging cell processing technologies and forecasts their impact on the commercialization process.
- Comprised of experts in process development, manufacturing, and emerging technologies <u>View current roster</u>
- Monthly meetings feature current events discussion, and webinar and publication planning

Business Models and Investment (BM&I) Subcommittee

- Addresses the evolving cell and gene therapy business model with and key considerations including clinical development, partnerships, financing, and commercialization.
- Comprised of investors, business development executives, and interested members. <u>View current roster</u>
- Monthly meetings feature current events discussion, and webinar and publication planning

Market Access and Patient Advocacy (MAPA) Subcommittee

- Addresses challenges associated with getting cell and gene therapies to patients including clinical trial management, reimbursement, and regional harmonization.
- Comprised of experts in clinical education, manufacturing, and clinical trial development. <u>View current roster</u> 15
- · Bi-monthly meetings feature current events discussion and webinar and publication planning



TACKLING PROMINENT INDUSTRY CHALLENGES

The ISCT industry community actively develops thought leadership programs and resources including guidance publications, state of the industry reports, and flagship programs uniting key stakeholders.



Recent Publications:

Cell and gene therapy: a snapshot of investor perspectives (Cytotherapy, 2020). Link to article

Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies (*Cytotherapy*, 2020) <u>Link to article</u>

A roadmap for cost-of-goods planning to guide economic production of cell therapy products (*Cytotherapy*, 2017) Link to article



<u>2020 Report</u> on Clinical Breakthroughs: Transforming the Standard of Care

2019 Report on Patients First: Achieving Global CGT Adoption

2018 Report on Addressing Translational Manufacturing Viability in Cell Therapy



Founded in 2018 by the Business Models & Investment Subcommittee, the "I to I" program aims to bridge the knowledge gap between two critical stakeholders in the International Society translational pipeline. Learn more.

Cell & Gene Therapy

Special offer for lab teams within ISCT Industry Member companies

LAB MEMBERSHIP FREE

(\$500 Base Fee) (Lab Director/Manager)

INCLUDES:

- Cytotherapy[®] subscription (hard copy & electronic copy)
- Member rates for website career posting

PATRON MEMBERS:

5 Free Tech Accounts PARTNER MEMBERS:

3 Free Tech Accounts

TECHNOLOGISTS

(\$25 per individual)

Eligibility for Technologist Abstract

ADDITIONAL REGULAR MEMBERS

(\$175 per individual) (i.e., Non-technologists)

SUPPORTER MEMBERS: 2 Free Tech Accounts

Awards

Cytotherapy® electronic subscription (or \$250 USD for hard copy subscription)

All members receive:

- Access to all ISCT member web resources
- Member discounted rates to all ISCT meetings and events
- Access to ISCT Member Networking Database
- Subscription to Telegraft members-only newsletter
- Eligibility to apply to join ISCT Committees



Start Your 2021 Industry Membership Today

Be part of a truly global community advancing cellular therapy

Madeline St. Onge
Associate Director, Marketing & Industry Affairs

madeline@isctglobal.org

www.isctglobal.org